16 June 2026.

Atmo Biosciences is proud to announce that it has been named a winner of Fast Company’s 2026 World Changing Ideas Awards. This annual recognition honors bold and transformative efforts that tackle the world’s most pressing issues—from sustainability initiatives and AI developments to cutting-edge medical devices at the forefront of their field. Now in its ninth year, the World Changing Ideas Awards celebrate organizations and projects that are delivering measurable impact across industries.

Read More

April 15, 2025.

Atmo Biosciences today announced the successful assignment of its foundational patent portfolio from RMIT University. Under this agreement, RMIT has transferred all patents and associated intellectual property (IP) related to the Atmo Gas Capsule to Atmo Biosciences in exchange for an equity stake in the company. This IP was previously subject to an exclusive royalty-based license agreement between Atmo and RMIT.

Read More

March 4, 2025.

Today, Atmo Biosciences announced the publication of pivotal clinical study data in Clinical Gastroenterology and Hepatology. The study validates the Atmo Capsule for assessing whole and regional gastrointestinal transit times to assist with the diagnosis of motility disorders such as gastroparesis and slow transit constipation.

Read More

December 14, 2023.

Atmo Biosciences has reached its patient recruitment target ahead of schedule for its dysmotility pivotal clinical study.

More than 200 patients were recruited in a multi-site clinical trial to support a submission for initial U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders.

Read More